Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo closes two plants

This article was originally published in The Tan Sheet

Executive Summary

The private labeler is closing its Holland and Montague, Mich.-based manufacturing facilities and will "transfer its profitable product lines" from those locations to plants based in Allegan, Mich. and The Bronx, N.Y., Perrigo announces June 27. The firm will discontinue production for its unsuccessful psyllium-based laxatives and effervescent tablets. The closings correspond with Perrigo's business strategy to improve efficiency and successfully integrate Agis, an Israeli generics firm acquired in March 2005, the firm states. Perrigo estimates an $8 mil. pre-tax charge will be incurred during Q4 2006 (ending July 1) as well as a $3 mil. one-time cost during fiscal 2007 as a result of the plant closings. All 140 employees affected by the closing plants will be offered positions at the Allegan site, Perrigo says...

You may also be interested in...

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts